Report flags FDA concerns over unapproved GLP-1 products including retatrutide
The item points to regulator unease about weight-loss products sold outside approved channels, with retatrutide named among the unapproved agents.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 30 08:23 ETSource: polskieradio.pl
The wire
- 01The report centers on FDA concerns about unapproved GLP-1 weight-loss drugs, including retatrutide, circulating outside approved supply.
- 02Retatrutide has no marketing approval, so any clinic, pharmacy or patient sourcing it is operating in the gray market that regulators are watching.
- 03No specific enforcement action, letter or date is described in the item; details of any FDA step remain unconfirmed here.
From the source
Read at polskieradio.plfda concerns unapproved glp-1 drugs weight loss retatrutide
